Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study

Abstract

Objectives: Data about the efficacy of ertapenem for the treatment of bloodstream infections (BSI) due to ESBL-producing Enterobacteriaceae (ESBL-E) are limited. We compared the clinical efficacy of ertapenem and other carbapenems in monomicrobial BSI due to ESBL-E. Methods: A multinational retrospective cohort study (INCREMENT project) was performed (ClinicalTrials.gov identifier: NCT01764490). Patients given monotherapy with ertapenem or other carbapenems were compared. Empirical and targeted therapies were analysed. Propensity scores were used to control for confounding; sensitivity analyses were performed in subgroups. The outcome variables were cure/improvement rate at day 14 and all-cause 30 day mortality. Results: The empirical therapy cohort (ETC) and the targeted therapy cohort (TTC) included 195 and 509 patients, respectively. Cure/improvement rates were 90.6% with ertapenem and 75.5% with other carbapenems (P¼0.06) in the ETC and 89.8% and 82.6% (P ¼ 0.02) in the TTC, respectively; 30 day mortality rates were 3.1% and 23.3% (P¼0.01) in the ETC and 9.3% and 17.1% (P¼0.01) in the TTC, respectively. Adjusted ORs (95% CI) forcure/improvement with empirical and targeted ertapenem were 1.87 (0.24 – 20.08; P ¼0.58) and 1.04 (0.44 – 2.50; P ¼ 0.92), respectively. For the propensity-matched cohorts it was 1.18 (0.43 – 3.29; P¼ 0.74). Regarding 30 day mortality, the adjusted HR (95% CI) for targeted ertapenem was 0.93 (0.43 –2.03; P¼0.86) and for the propensity-matched cohorts it was 1.05 (0.46 – 2.44; P ¼0.90). Sensitivity analyses were consistent except for patients with severe sepsis/septic shock, which showed a non-significant trend favouring other carbapenems. Conclusions: Ertapenem appears as effective as other carbapenems for empirical and targeted therapy of BSI due to ESBL-E, but further studies are needed for patients with severe sepsis/septic shock